A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
EMD Serono
EMD Serono
Inimmune Corporation
TILT Biotherapeutics Ltd.
EMD Serono
Exelixis
EMD Serono
EMD Serono
Kyowa Kirin Co., Ltd.
Gilead Sciences
Merck KGaA, Darmstadt, Germany
Leap Therapeutics, Inc.
NKGen Biotech, Inc.
Fate Therapeutics
Fate Therapeutics
Genome & Company
Debiopharm International SA
Vyriad, Inc.
Pfizer
EMD Serono
Presage Biosciences
Pfizer
EMD Serono
Merck KGaA, Darmstadt, Germany
Pfizer
Pfizer